Holen Sie sich die Stockscreener-App
119.77
0.72%
0.815
Handel nachbörslich:
119.85
0.085
+0.07%
Guardant Health Inc Aktie (GH) Neueste Nachrichten
BTIG raises Guardant Health stock price target on FDA approval By Investing.com - Investing.com Canada
Guardant Health, Inc. (GH) Stock Analysis: 48.3% Revenue Growth Fuels Investor Optimism - DirectorsTalk Interviews
Guardant gets FDA nod for next-gen cancer mutation blood test - Mugglehead Investment Magazine
Guardant wins FDA nod for Guardant360 Liquid CDx cancer test - MSN
A Look At Guardant Health’s Valuation After Its Recent Share Price Surge - Yahoo Finance
Guardant Health (GH) Is Up 25.3% After FDA Clears First Genomic‑Epigenomic Liquid Biopsy Panel – Has The Bull Case Changed? - Yahoo Finance
Guardant Health Stock 5-Day Winning Spree: Stock Climbs 25% - Trefis
Guardant Health Stock On Fire: Up 25% With 5-Day Winning Streak - Trefis
Insider Sell: John Saia Sells 20,000 Shares of Guardant Health I - GuruFocus
Guardant Health director Ian T. Clark disposes of $735k in shares - Investing.com UK
Guardant Health chief legal officer sells $2.13m in stock - Investing.com UK
Guardant Health director Ian T. Clark disposes of $735k in shares By Investing.com - Investing.com South Africa
Guardant Health chief legal officer sells $2.13m in stock By Investing.com - Investing.com Australia
Guardant Health insider cashless exercise reported (NASDAQ: GH) - Stock Titan
[144] Guardant Health, Inc. SEC Filing - Stock Titan
Guardant Health Insider Sold Shares Worth $23,076,690, According to a Recent SEC Filing - Moomoo
Guardant Health Insider Sold Shares Worth $2,130,229, According to a Recent SEC Filing - Moomoo
Guardant Health (GH) Chief Legal Officer sells 20,000 shares in open-market trades - Stock Titan
Guardant Health (GH) co-CEO’s family trust sells 210K shares of stock - Stock Titan
Family trust of Guardant Health (NASDAQ: GH) director sells 6,876 shares in open market - Stock Titan
Guardant Health (NASDAQ: GH) director sells 1,250 shares after exercising options - Stock Titan
Guardant Health stock gains on early FDA approval for G360 test By Investing.com - Investing.com South Africa
Guardant Health stock hits 52-week high at 120.74 USD By Investing.com - Investing.com Nigeria
Research Alert: CFRA Maintains Buy Rating On Shares Of Guardant Health - Moomoo
Guardant Health stock hits 52-week high at 120.74 USD - Investing.com
Guardant Health stock gains on early FDA approval for G360 test - Investing.com Australia
Guardant wins FDA approval for updated liquid biopsy - MedTech Dive
NORTH SQUARE DYNAMIC SMALL CAP FUND's Guardant Health Inc(GH) Holding History - GuruFocus
Guardant Health leaps on a major win in cancer detection; will shares break out? - MSN
Guardant Health (GH) Shares Rise Following FDA Approval of Guard - GuruFocus
Why Guardant Health (GH) Is Up 16.8% After Hiking 2026 Revenue Guidance on Shield Momentum - simplywall.st
Guardant Health (GH) Gains FDA Approval for New Liquid Biopsy Te - GuruFocus
Guardant Health secures FDA approval for expanded liquid biopsy test - MSN
Guardant Health (GH) Form 144 lists brokered proposed sales and restricted stock lapses - Stock Titan
Guardant Health (NASDAQ: GH) affiliate sale notice; 1,300 shares sold previously - Stock Titan
Guardant Health Stock Climbs As Q1 Beat Fuels Bullish Targets - StocksToTrade
Guardant Health receives FDA approval for expanded liquid biopsy test By Investing.com - Investing.com Australia
Guardant Health Stock Climbs As Growth Story Accelerates - timothysykes.com
Guardant Health Stock Rallies After Shield-Fueled Earnings Beat - StocksToTrade
Why is Guardant Health stock surging today? By Investing.com - Investing.com Australia
Guardant Health Secures FDA Approval For Expanded Liquid Biopsy TestGuardant Health (NASDAQ:GH) - Benzinga
FDA approval advances personalized cancer diagnostics - BioWorld News
Guardant Health Stock Jumps 10% to $108 on Momentum From Record Q1 Revenue Beat and Raised Guidance - International Business Times Australia
Guardant Health Stock Builds Momentum After Q1 Beat And Analyst Upgrades - timothysykes.com
Guardant Health Receives FDA Approval for New Cancer Test - Intellectia AI
Quinn Emanuel Gets $3 Million Sanction in Drug Advertising Case - Bloomberg Law News
Guardant wins FDA nod for Guardant360 Liquid CDx (GH:NASDAQ) - Seeking Alpha
Guardant Health Receives FDA Approval for New Liquid Biopsy - Intellectia AI
Guardant Health receives FDA approval for expanded liquid biopsy test - Investing.com
Guardant Health Says US FDA Approved Liquid Biopsy Test - Moomoo
Fda approves new Guardant360 liquid cdx, the largest FDA-approved liquid biopsy panel with a 100x expanded footprint - marketscreener.com
New cancer blood test gains FDA approval with 100x wider gene view - Stock Titan
FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint - Business Wire
Blood Based Biomarkers Market is expected to Hit US$ 41.43 - openPR.com
Quinn Emanuel Owes More Sanctions In Guardant Fight - Law360
Guardant Health (GH) director sells 116 shares after exercising 250 RSUs - Stock Titan
1.43%
0.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):